布地奈德雾化对慢性阻塞性肺疾病合并糖尿病患者的疗效及糖代谢的影响(英文)  

Efficacy of inhaled budesonide on chronic obstructive pulmonary disease concurrent with diabetes and glycometabolism in patients

作　　者：李向阳[1] 顾芹[2] 盛华[1] 沈维敏[1] 

机构地区：[1]复旦大学附属华东医院呼吸科,上海200040 [2]复旦大学附属华东医院内分泌科,上海200040

出　　处：《中国临床药学杂志》2008年第5期262-264,共3页Chinese Journal of Clinical Pharmacy

摘　　要：目的探讨布地奈德雾化吸入在慢性阻塞性肺疾病合并糖尿病患者中的疗效及对糖代谢的影响。方法60例患者随机分成2组,布地奈德组予氧启动雾化吸入布地奈德混悬液2mg,bid+异丙托溴铵雾化吸入液500μg,bid;对照组予氧启动雾化吸入异丙托溴铵雾化吸入液500μg。治疗前后测定肺功能一秒钟用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%),动脉血氧分压(PaO_2),及血糖(FPG),糖化血红蛋白(HbA_(?)c)。结果57例完成试验,治疗3 mo后,布地奈德组FEV1由(1.27±0.20)L升至(1.49±0.21)L(P<0.01),FEV1%由(64.14±6.37)升至(74.76±7.62),(P<0.01),和对照组相比差异有统计学意义(P<0.05),治疗6 mo后的FEV1、FEV1%和3 mo相比差异无统计学意义(P>0.05)。布地奈德组FPG、HbA_(?)c治疗前后差异无统计学意义(P>0.05)。结论在慢性阻塞性肺疾病合并糖尿病患者中,布地奈德雾化吸入治疗3-6 mo可改善肺通气功能,而对于血糖则无影响。AIM To evaluate the clinical efficacy of inhaled budesonide on chronic obstructive pulmonary disease （COPD） patients with diabetes. METHODS Sixty patients with stable COPD and diabetes were randomly divided into two groups： budesonide group and control group. Both groups were received ipratropium bromide 500 μg twice a day by the inhalation of oxygen-driven. Budesonide group was also inhaled budesonide 2 mg twice a day. Forced expiratory volume in one second （ FEV1 ） , FEV 1 pred （FEV1% ）, arterial partial pressure of oxygen（PaO2）, fasting plasma glucose （FPG） and glycated haemoglobin （HbA1c） were measured before and after treatment for 3 , 6 months. RESULTS After 3 months, FEV1 of patients in budesonide group was improved from （ 1.27±0.20） L to （ 1.49±0.21 ） L （ P 〈 0.01） and FEV1% was improved from （64.14±6.37） to （74.76±7.62） （P 〈 0.01）which was significant higher than that in control group （ P 〈 0. 05）. The PaO2, FPG, HbA1 c of all the patients were not significant during the test （ P 〉 0. 05）. CONCLUSION The study suggests that the treatment with inhaled budesonide could improve pulmonary ventilation function without affecting the glucose metabolism.

关 键 词：布地奈德 慢性阻塞性肺疾病 肺功能 糖代谢 

分 类 号：R563.9[医药卫生—呼吸系统] R587.1[医药卫生—内科学]